BioCryst Pharmaceuticals, Inc. - Common Stock · Transaction Jul 10, 2026 · Filed Sep 4, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · BCRX
-1.72% · -$0.1400 · Vol 2.8M
Live · updated 11:53:39 ET
BioCryst Pharmaceuticals Inc
Biotechnology
$7.98
Follow $BCRX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $BCRX by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredThu Oct 1 · last completed session · daily score · 17h old · BCRX
MethodologyBCRX
BioCryst Pharmaceuticals Inc
Thu Oct 1 · last completed session · daily score · 17h old
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
71/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 1 · last completed session · daily score · 17h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is BCRX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About BioCryst Pharmaceuticals Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
1994
Employees
435
Country
US
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$8.12
Day high
$8.13
Day low
$7.92
Previous close
$8.12
52W high
$11.11
-28.17% from high
52W low
$6.24
36% of range
Market cap
$2.1B
P/E
7.95×
EPS
$-2.6000
Beta
0.47
Shares out
255.5M
Volume
2.8M
0.59× rel vol
Avg volume
4.7M
VWAP
$8.00
Price history computed in-house
1W
-7.10%
1M
-21.53%
3M
-18.90%
1Y
+8.87%
YTD
+2.31%
SMA 50 $9.25 · below
SMA 200 $8.68 · below
52W position 36%
BCRX overview
Related filings and maps
Public disclosures
Congress activity in BCRX
Official filing ↗
BioCryst Pharmaceuticals, Inc. - Common Stock · Transaction Nov 13, 2025 · Filed Dec 15, 2025 · $1,001 to $15,000
BioCryst Pharmaceuticals, Inc. · Transaction Oct 16, 2023 · Filed Nov 11, 2023 · $1,001 to $15,000
BioCryst Pharmaceuticals, Inc. · Transaction Sep 15, 2023 · Filed Oct 15, 2023 · $1,001 to $15,000
BioCryst Pharmaceuticals, Inc. · Transaction Aug 11, 2022 · Filed Sep 16, 2022 · $1,001 to $15,000
Federal contracts
BCRX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BCRX in this window.
Lobbying spend
BCRX lobbying filings, year to date.
Registered lobbying filings matched to BioCryst Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BCRX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for BCRX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.